News and Trends 26 Oct 2017 Here’s a Flashy New Technique to Model Disease Although we have come very far in understanding cells and their functions, many undiscovered characteristics still keep us in the dark. Creating experiments that mimic the cell’s in vivo environments as closely as possible is one of the many challenges researchers face when working with cells in their labs. Micropatterning is a technique that addresses […] October 26, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 26 Oct 2017 Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses Serial entrepreneur John Beadle is now at the helm of PsiOxus, an Oxford biotech with some promising virus-based cancer treatments. Oncolytic viruses have been around for a while without much to show for themselves besides Amgen’s Imlygic, but PsiOxus, one of our top Oxford biotechs, has some ideas to make them bear fruit. The company […] October 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A – a bleeding disorder caused by a lack of clotting factor VIII activity in the […] October 25, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 British Researchers Develop Clever Nanoparticles to Kill Cancer Cells The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […] October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 The UK Recommends the use of GSK’s €594,000 Gene Therapy Amidst uncertainty about the commercial future of expensive gene therapies, the UK’s NICE has declared GSK’s Strimvelis offers “value for money.” Approved by the EMA last year, Strimvelis is one of the most expensive drugs on the market. Although GSK is offering a money-back guarantee and payment through instalments, the price of the gene therapy, […] October 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 25 Oct 2017 What Could RNA Therapies Do for the Treatment of CNS Disorders? Evelyn chatted with Thomas de Vlaam to find out what his company, Amylon, is working on and how it hopes to change the field fighting CNS disorders. De Vlaam came up with AT-010, a drug candidate for the treatment of Katwijk‘s disease, during his time at ProQR. When it became clear that he had something […] October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […] October 24, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 British Scientists Prove that it Takes Very Few Mutations to Cause Cancer Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market Montpellier-based Deinove has developed a bacterial anti-aging skincare product, which has shown its safety and healing capacity in studies so far. Deinove specializes in high-value compounds from rare bacteria, in particular, the Deinococcus genus. It has announced that it will launch its first cosmetic product into the anti-aging skincare market in 2018, which is based on a […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Oct 2017 Where to Find the Money to Get Your Biotech Startup Up with the Big Boys What do you need to kickstart your own biotech company? A great idea, of course. Industry knowledge, a plus. Money… This could be tricky. Breaking into the biotech industry is one of the most expensive decisions that you can make. First, you need ground-breaking science that has what it takes to change its respective field, […] October 24, 2017 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety […] October 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Transgene‘s Hepatitis B Vaccine Does the Business at Phase I The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has […] October 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email